Lowenstein Sandler represented TherapyMatch, Inc. [dba Headway] in the transaction. TherapyMatch, Inc. [dba Headway] closed its $100 million Series D funding round to support its planned...
You must be a Standard 1 Year member to access this content.
Lowenstein advised Hildred Capital Management and Crown Laboratories on the deal, while Gibson, Dunn & Crutcher advised StriVectin and L Catterton. Hildred Capital Management (Hildred) and...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Progress on the deal, while Lowenstein represented Mill Point Capital. Progress, the leading provider of products to develop, deploy...
You must be a Standard 1 Year member to access this content.
